[go: up one dir, main page]

DK0900380T3 - Method for Selection and Preparation of T-Cell Peptide Epitopes and Vaccines Containing These Selected Epitopes - Google Patents

Method for Selection and Preparation of T-Cell Peptide Epitopes and Vaccines Containing These Selected Epitopes

Info

Publication number
DK0900380T3
DK0900380T3 DK97919749T DK97919749T DK0900380T3 DK 0900380 T3 DK0900380 T3 DK 0900380T3 DK 97919749 T DK97919749 T DK 97919749T DK 97919749 T DK97919749 T DK 97919749T DK 0900380 T3 DK0900380 T3 DK 0900380T3
Authority
DK
Denmark
Prior art keywords
epitopes
vaccines
cell
present
selection
Prior art date
Application number
DK97919749T
Other languages
Danish (da)
Inventor
Der Burg Sjoerd Henricus Van
Wybe Martin Kast
Reinaldus Everardus Maria Toes
Rienk Offringa
Cornelius Johannes Mari Melief
Original Assignee
Seed Capital Investments
Univ Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seed Capital Investments, Univ Leiden filed Critical Seed Capital Investments
Application granted granted Critical
Publication of DK0900380T3 publication Critical patent/DK0900380T3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to the field of molecular biology and immunology. In particular it relates to vaccines and methods for providing vaccines which elicit immune responses when administered to a mammal, in particular a human. The preferred elicited immune response is a T cell response, elicited by peptide T cell epitopes. These vaccines find their application in many fields ranging from cancer treatments to treatments of prophylaxis of infectious diseases such as Aids. The present invention provides novel methods for selecting the peptide sequences from an intact antigen which will lead to a proper (T cell) immune response upon administration in a suitable vehicle. The epitopes and vaccines are, of course, also part of the present invention.
DK97919749T 1996-04-26 1997-04-28 Method for Selection and Preparation of T-Cell Peptide Epitopes and Vaccines Containing These Selected Epitopes DK0900380T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96201145 1996-04-26
EP96203670 1996-12-23
PCT/NL1997/000229 WO1997041440A1 (en) 1996-04-26 1997-04-28 Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopes

Publications (1)

Publication Number Publication Date
DK0900380T3 true DK0900380T3 (en) 2003-11-03

Family

ID=26142751

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97919749T DK0900380T3 (en) 1996-04-26 1997-04-28 Method for Selection and Preparation of T-Cell Peptide Epitopes and Vaccines Containing These Selected Epitopes

Country Status (11)

Country Link
US (1) US20070025968A1 (en)
EP (1) EP0900380B1 (en)
JP (1) JP4108126B2 (en)
AT (1) ATE244891T1 (en)
AU (1) AU738649B2 (en)
CA (1) CA2252675A1 (en)
DE (1) DE69723434T2 (en)
DK (1) DK0900380T3 (en)
ES (1) ES2205209T3 (en)
PT (1) PT900380E (en)
WO (1) WO1997041440A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
US6326200B1 (en) * 1997-06-23 2001-12-04 Ludwig Institute For Cancer Research Isolated nona-and decapeptides which bind to HLA molecules, and the use thereof
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
GB9804121D0 (en) * 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
EP1078092B1 (en) * 1998-05-13 2011-08-03 Epimmune Inc. Expression vectors for stimulating an immune response and methods of using the same
DK1616579T3 (en) 1998-05-23 2009-09-14 Univ Leiden Medical Ct CD40 binding molecules and CTL peptides for the treatment of tumors
DE69940774D1 (en) * 1998-06-17 2009-06-04 Idm Pharma Inc HLA-Binding PEPTIDES AND ITS USES
DE69935599T2 (en) 1998-08-21 2007-11-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services MODIFIED HCV PEPTIDE VACCINES
US6962790B1 (en) 1998-09-23 2005-11-08 University Of Massachusetts Medical Center Predictive assay for immune response
FR2794370B1 (en) * 1999-06-03 2003-10-17 Biovector Therapeutics POLYEPITOPIC PROTEIN FRAGMENTS, THEIR OBTAINMENT AND THEIR USES IN PARTICULAR IN VACCINATION
AU7917200A (en) * 1999-09-30 2001-04-30 Institut Pasteur Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis b virus sequences
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
CA2386341A1 (en) 1999-11-18 2001-05-25 Epimmune Inc. Heteroclitic analogs and related methods
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
CA2394748A1 (en) * 1999-12-28 2001-07-05 Epimmune Inc. Optimized minigenes and peptides encoded thereby
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
DE60142615D1 (en) * 2000-04-28 2010-09-02 Mannkind Corp EPITOP SYNCHRONIZATION IN ANY PRESENTING CELLS
US7342002B2 (en) 2000-08-03 2008-03-11 The Johns Hopkins University Molecular vaccine linking an endoplasmic chaperone polypeptide to an antigen
SI1311542T1 (en) * 2000-08-21 2009-02-28 Apitope Technology Bristol Ltd Tolerogenic peptides
AU2000275748A1 (en) * 2000-09-01 2002-03-22 Epimmune, Inc. Hla-a2.1 binding peptides and their uses
US7189513B2 (en) 2001-03-23 2007-03-13 The United States Of America As Represented By The Department Of Health And Human Services Human papilloma virus immunoreactive peptides
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
EP1752160A3 (en) * 2001-04-06 2007-05-30 Mannkind Corporation Epitope sequences
WO2002094313A2 (en) * 2001-05-18 2002-11-28 Powderject Vaccines, Inc. Vaccine composition
CN101024842A (en) 2001-11-07 2007-08-29 曼康公司 Expression vectors encoding epitopes of target-associated antigens and its design method
WO2004098526A2 (en) 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
DE10347710B4 (en) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Recombinant vaccines and their use
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
JP2008044848A (en) * 2004-11-30 2008-02-28 Univ Kurume HLA-A24 restricted tumor antigen peptide
CA2594040A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
DE102005046490A1 (en) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz New nucleic acid molecule comprising promoter, a transcriptable nucleic acid sequence, a first and second nucleic acid sequence for producing modified RNA with transcriptional stability and translational efficiency
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
EP2023143A1 (en) 2007-08-06 2009-02-11 Boehringer Ingelheim Vetmedica Gmbh Immunogenic streptococcus proteins
WO2009125394A1 (en) 2008-04-09 2009-10-15 Technion Research & Development Foundation Ltd. Anti human immunodeficiency antibodies and uses thereof
MX360823B (en) 2011-05-24 2018-11-16 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Individualized vaccines for cancer.
CN109172819A (en) 2011-07-29 2019-01-11 西莱克塔生物科技公司 Generate the synthesis nano-carrier of body fluid and cytotoxic T lymphocyte (CTL) immune response
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
JP6484558B2 (en) 2012-11-28 2019-03-13 バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｇｍｂｈ Combination of cancer vaccine
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
CN105175498A (en) * 2015-10-09 2015-12-23 深圳市康尔诺生物技术有限公司 Heat shock protein complex associated with cervical cancer and application of heat shock protein complex
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
JPWO2019054409A1 (en) * 2017-09-12 2020-11-12 国立大学法人北海道大学 Screening methods and screening kits for substances that interact with HLA proteins
WO2020086927A1 (en) * 2018-10-26 2020-04-30 Saint Louis University Peptides for inducing heterosubtypic influenza t cell responses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294322B1 (en) * 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
CA2158281A1 (en) * 1993-03-15 1994-09-29 Jay A. Berzofsky Peptide coated dendritic cells as immunogens
AU7958994A (en) * 1993-10-05 1995-05-01 Ludwig Institute For Cancer Research Method for provoking immunity by peptides labelled with a photoactivatable group which binds to mhc molecules
WO1996022067A2 (en) * 1994-12-27 1996-07-25 United Biomedical, Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics

Also Published As

Publication number Publication date
ATE244891T1 (en) 2003-07-15
US20070025968A1 (en) 2007-02-01
AU738649B2 (en) 2001-09-20
PT900380E (en) 2003-12-31
JP2000510689A (en) 2000-08-22
JP4108126B2 (en) 2008-06-25
WO1997041440A1 (en) 1997-11-06
ES2205209T3 (en) 2004-05-01
AU2410697A (en) 1997-11-19
EP0900380B1 (en) 2003-07-09
EP0900380A1 (en) 1999-03-10
DE69723434T2 (en) 2004-05-19
DE69723434D1 (en) 2003-08-14
CA2252675A1 (en) 1997-11-06

Similar Documents

Publication Publication Date Title
DK0900380T3 (en) Method for Selection and Preparation of T-Cell Peptide Epitopes and Vaccines Containing These Selected Epitopes
DK1104306T3 (en) Preparations of CpG and Saponin Adjuvants and Methods for Using Them
DK1090039T3 (en) Peptide composition as immunogen for the treatment of allergy
ATE277633T1 (en) PREPARATIONS AND METHODS FOR TRIGGERING CTL IMMUNITY
DK1098910T3 (en) Antigen Complex Containing Immune Stimulating Peptide, CD4 and Chemokine Receptor Domain for the Treatment of HIV and Immune Diseases
CA2290485A1 (en) Method for the production of non-immunogenic proteins
AU1800597A (en) Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
DK101888A (en) IMMUNO MODULATING AGENTS AND APPLICATION OF THESE
DK1267924T3 (en) Immunotherapeutic methods and compositions
DK1003552T3 (en) LO-CD2a antibody and its uses for inhibiting T cell activation and proliferation
EP1385541A4 (en) IMMUNOSTIMULANT COMPOSITIONS COMPRISING AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND QS-21
Franke et al. Pan DR binding sequence provides T-cell help for induction of protective antibodies against Plasmodium yoelii sporozoites
Rolph et al. CD40 signaling converts a minimally immunogenic antigen into a potent vaccine against the intracellular pathogen Listeria monocytogenes
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
EP0753009B1 (en) Malaria peptides
Delavari et al. Pseudomonas aeruginosa flagellin as an adjuvant: superiority of a conjugated form of flagellin versus a mixture with a human immunodeficiency virus type 1 vaccine candidate in the induction of immune responses
WO1999064464A3 (en) Method for producing or enhancing a t-cell response against a target cell using a complex comprising an hla class i molecule and an attaching means
DK0701612T3 (en) Immunogenic Preparation of OspC Antigen Vaccines for Prevention and Treatment of Lyme Disease and Recombinant Method for Preparation
Bittner‐Eddy et al. Identification of gingipain‐specific I‐A b‐restricted CD 4+ T cells following mucosal colonization with P orphyromonas gingivalis in C 57 BL/6 mice
Chowdhury et al. Generation of high titer antisera in rabbits by DNA immunization
AU7520398A (en) Test kit for tuberculosis diagnosis or the like
WAHLGREN et al. Epitopes of the Plasmodium falciparum clustered‐asparagine‐rich protein (CARP) recognized by human T‐cells and antibodies
DK0952771T3 (en) New Saponin Preparations and Uses thereof
Kamali et al. Experimental immunization based on plasmodium antigens isolated by antibody affinity
Dos Santos et al. RNA and protein immunization with Trypanosoma cruzi trans-sialidase containing SAPA repeats protects mice against infection and promotes a balanced inflammatory response